Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Cullinan Therapeutics (NASDAQ:CGEM) and maintained a price target of $36.
May 16, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Cullinan Therapeutics and maintained a price target of $36.
The reiteration of an Outperform rating and the maintenance of a $36 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100